AKT1 and leukemia: MK-2206, a potent oral allosteric AKT inhibitor that enhances the antitumour potency of chemotherapeutic agents (Ji et al. 2017), had no effect on normal peripheral blood mononuclear cells, but induced G1-phase arrest and apoptosis in leukemia cells (Lu et al. 2015), and induction of apoptosis by combined treatment of bufalin in multiple myeloma cells (Xiang et al. 2017).